The epidemic of diabetes has been fueled by a parallel increase in the prevalence of overweight and obesity. Both diabetes and overweight/obesity have become major public health problems causing increased morbidity and mortality and are important risk factors for cardiovascular disease. Cardiovascular disease is the leading cause of death in China. Excess weight has been shown to be associated with increased prevalence of type 2 diabetes, hypertension, dyslipidemia, metabolic syndrome and certain cancers; while weight loss dramatically reduces these obesity-related diseases. Overweight and obesity are important modifiable risk factors for diabetes and cardiovascular disease. There has also been encouraging progress in treatments for obesity. In 2013, the American Medical Association declared obesity a ＂disease state＂ requiring a range of medical interventions to advance obesity treatment and prevention. Since 2012, four new drugs have been approved by the U.S. FDA for the treatment of obesity.
目的:探讨ADR技术在经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)开通冠状动脉慢性完全闭塞(chronic total occlusion,CTO)应用的有效性与安全性。方法:选取2017年1月至2018年12月在滨州市人民医院和南昌大学第二附属医院行PCI的CTO病变中未使用正向夹层再次进入(antegrade dissection re-entry,ADR)技术的48例患者(对照组)和使用ADR技术的50例患者(治疗组)为研究对象。比较2组患者的基线情况、冠状动脉造影结果、PCI成功率和随访12个月的主要不良心血管事件(major adverse cardiovascular events,MACE)。结果:对照组共有52处CTO病变,治疗组共有58处CTO病变。治疗组PCI成功率明显高于对照组(89.7%vs.71.2%,P=0.047),其中6例支架内再狭窄型CTO(in-stent restenosis,ISR-CTO)病变全部开通,治疗组平均PCI时间[(71±25) min vs.(95±33) min,P=0.041]、X线曝光时间[(42±17) min vs.(71±22) min,P=0.032]、对比剂使用剂量[(98±26) mL vs.(178±63) mL,P=0.029]明显低于对照组,差异均有统计学意义。治疗组随访12个月MACE发生率(22.0%vs.41.7%,P=0.046)及再发心肌梗死发生率(10.0%vs.27.1%,P=0.047)明显低于对照组,差异有统计学意义。结论:冠状动脉CTO病变PCI时,应用ADR技术安全、有效,缩短了手术时间,降低了医患的辐射剂量及对比剂的使用剂量,改善了患者预后。
